Trinity Biotech has announced a strategic partnership with Latch Medical to advance drug delivery solutions guided by continuous glucose monitoring (CGM) technology. This collaboration aims to integrate Trinity Biotech's CGM+ biosensor platform with Latch Medical's innovative intradermal drug delivery system, potentially enhancing treatment options for metabolic conditions such as diabetes and obesity.
The partnership will leverage real-time metabolic data from the CGM+ platform to optimize therapeutic delivery, thereby enabling personalized treatment approaches. Trinity Biotech's CEO, John Gillard, emphasized the importance of merging biosensing with AI and precision drug delivery, suggesting that this integrated approach could significantly improve patient outcomes.
As part of the collaboration, Trinity Biotech plans to make an equity investment in Latch Medical, reflecting confidence in the potential of intradermal delivery technologies. This investment comes with support from Perceptive Advisors, a key financial backer of Trinity Biotech.
This collaboration not only expands the applications of CGM+ beyond mere monitoring but also aligns with Trinity Biotech's strategy to create a comprehensive metabolic health platform. The partnership signifies a promising step towards more personalized healthcare solutions, addressing the growing market of metabolic diseases.